ArticleAmerican journal of translational research2026
Application value and safety advantages of remimazolam tosilate in sedation for emergency rescue endotracheal intubation.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEmergency tracheal intubation is a high-risk, life-support procedure that requires rapid and safe sedation. This study aimed to evaluate the clinical effectiveness and safety of remimazolam tosilate compared to propofol for sedation during emergency resuscitation intubation.
methodsThis retrospective cohort study included adult patients who underwent sedation-assisted emergency intubation between June 2022 and June 2025. Patients were grouped according to the primary sedative administered: propofol or remimazolam. Sedation depth was assessed using the Ramsay score, and intubation success rates were recorded. Hemodynamic indices and respiratory rates were documented pre- and post-intubation. The incidence of adverse events and cognitive function at postoperative 72 hours were also evaluated.
resultsA total of 216 patients were included (104 in the propofol group and 112 in the remimazolam group). Propofol demonstrated a faster onset of sedation (42.12 ± 6.63 vs. 95.12 ± 10.17 seconds, P < 0.001), whereas remimazolam achieved a significantly higher first-attempt intubation success rate (87.50% vs. 66.35%, P < 0.001). After intubation, patients in the remimazolam group maintained higher systolic blood pressure (122.20 ± 9.77 vs. 116.42 ± 17.38 mmHg, P=0.003) and mean arterial pressure, as well as a lower rate-pressure product (10395.81 ± 928.89 vs. 10754.15 ± 1168.58 mmHg/min, P=0.014). The remimazolam group also exhibited lower incidences of hypotension (9.82% vs. 20.19%, P=0.032) and respiratory depression (5.36% vs. 17.31%, P=0.005), and experienced less injection pain (5.36% vs. 27.88%, P < 0.001).
conclusionsIn emergency intubation, compared to propofol, remimazolam tosilate demonstrated a slower onset of sedation but offers better hemodynamic stability, higher first-attempt success rates, more favorable respiratory profiles, and improved early cognitive recovery, making it a valuable alternative sedative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.